News and Trends 7 Jul 2020
Hansa Biopharma Gets up to €350M to Make Gene Therapy Work in Resistant Patients
…to those patients that are naturally resistant to the AAV vectors used to deliver these treatments. According to the agreement, Hansa will get €8.8M ($10M) upfront and is eligible for…